TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To improve asthma outcomes by developing and evaluating strategies for enhancing the clinic-patient partnership. To develop a model of shared decision-making for asthma treatment, and to evaluate it in a two-year randomized clinical trial in 342 adults aged 18-70 years with sub-optimally controlled persistent asthma.


Options:
A: Inclusion Criteria:

* All patients in primary care referred to Diabetes Educator
B: Inclusion: Asthma not well-controlled; doctor-diagnosed asthma; currently taking asthma medications; 12 % and 200ml increase in FEV1 after 2 puffs of an inhaled short-acting -agonist (SABA) bronchodilator ; 2 or more control problems identified using the ATAQ asthma control instrument; 18-70 years of age; willing to be randomized to one of the three treatment arms and to participate in follow-up for 2 years; Kaiser Permanente member for 1 year

Exclusion: Mild intermittent asthma, defined as either seasonal asthma or (daytime asthma symptoms \<2x/week and nocturnal symptoms \<2x/month and no use of controller medications); under the ongoing care of an allergist or pulmonologist; regular use of oral corticosteroids; currently receiving case-management for their asthma; unable to speak, read or understand English; planning to leave the catchment area within the next two years
C: Inclusion Criteria:

* Diagnosis of type 2 diabetes (medication and HbA1c\>7% and no cardiovascular disease), coronary artery disease (history of myocardial infarction or revascularisation) or heart failure (NYHA II-III and admitted in a hospital for the condition within 2 years)
* Aged 45 years or older
* Resident in the Päijät-Häme health care district

Exclusion Criteria:

* Classified as ineligible by primary care physician
* Unable to co-operate or participate in health coaching
* Major elective surgery planned within 6 months
* History of major surgery within past 2 years
* Life expectancy \<1 year
* Pregnancy
D: Inclusion Criteria:

* Diabetes with most recent HbA1c 8 or above in past 6 months.

Exclusion Criteria:

* Dementia,
* Life expectancy less than 6 months,
* Inability to speak English or Spanish.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To improve asthma outcomes by developing and evaluating strategies for enhancing the clinic-patient partnership. To develop a model of shared decision-making for asthma treatment, and to evaluate it in a two-year randomized clinical trial in 342 adults aged 18-70 years with sub-optimally controlled persistent asthma.


Options:
A: Inclusion Criteria:

* age 15 or older
* physician diagnosed asthma
* regular use of prescribed asthma medication over preceding year
* post-bronchodilator FEV1 of at least 75% of predicted
* inadequate asthma control over preceding two months

Exclusion Criteria:

* current or past smoking (greater than 10 pack-years)
* serious asthma exacerbation within previous three months
* regular use of oral corticosteroids
* history of respiratory failure due to asthma
* current use of montelukast or history of adverse reaction to montelukast
* concomitant interfering medical condition
* participation in another clinical trial
* inability or unwillingness to perform study procedures
* pregnancy, lack of effective contraception (when appropriate), lactation
B: Inclusion Criteria:

* 6-14 year old children with a history of asthma for at least 12 months
* must demonstrate airway constriction brought on by exercise

Exclusion Criteria:

* is taking any medications that are not allowed in the study
C: Inclusion: Asthma not well-controlled; doctor-diagnosed asthma; currently taking asthma medications; 12 % and 200ml increase in FEV1 after 2 puffs of an inhaled short-acting -agonist (SABA) bronchodilator ; 2 or more control problems identified using the ATAQ asthma control instrument; 18-70 years of age; willing to be randomized to one of the three treatment arms and to participate in follow-up for 2 years; Kaiser Permanente member for 1 year

Exclusion: Mild intermittent asthma, defined as either seasonal asthma or (daytime asthma symptoms \<2x/week and nocturnal symptoms \<2x/month and no use of controller medications); under the ongoing care of an allergist or pulmonologist; regular use of oral corticosteroids; currently receiving case-management for their asthma; unable to speak, read or understand English; planning to leave the catchment area within the next two years
D: Inclusion Criteria:

* physician-diagnosed asthma
* age 6 or older
* pre-bronchodilator forced expiratory volume (FEV1) of at least 60% of predicted
* beta-agonist reversibility OR airways hyperreactivity by methacholine challenge
* Juniper Asthma Control Score of 1.5 or greater if not on daily controller
* good current health

Exclusion Criteria:

* current or past smoking (greater than 20 pack-years)
* chronic or current oral steroid therapy
* pregnancy, lack of effective contraception (when appropriate), lactation

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Zinc Therapy in Zinc Deficient HIV Positive Drug Users
Brief Summary: Zinc deficiency is prevalent in HIV infected individuals who abuse drugs. The purpose of this study is to determine if zinc therapy will prevent immune failure in HIV infected individuals who abuse drugs and have low plasma zinc levels.


Options:
A: Inclusion Criteria:

* Children aged between 3-14 years hospitalized at ICDDR, B presenting with cholera within 24 hours of onset.
* Stool output more than 4ml/kg/hour within the first 6 hours of observation period.
* Positive dark field examination

Exclusion Criteria:

* Unable to rehydrate within 6 hours
* Negative dark field examination
* Systemic illness requiring immediate administration of antibiotics.
* Received antibiotics in the 24 hours prior to hospitalization
* Patients presenting with bloody mucoid diarrhea
* Unconscious or medical emergencies
B: Inclusion Criteria:

1. Children less than 5 years with acute watery diarrhoea less than 48 h of duration
2. No medication received other than ORS or home solution
3. Absence of complication or co-morbidities.
4. Absence of severe dehydration

Exclusion Criteria:

1. Age greater than 5 years
2. Diarrhoea more than 48 h duration
3. Unable to eat or drink
4. Already received multiple treatment including zinc
5. Presence of co-morbidities
6. Severe dehydration
C: Inclusion Criteria:

* HIV infected
* Drug User
* Blood zinc level greater than 0.35 mcg/mL and less than 0.75mcg/ml

Exclusion Criteria:

* Currently participating in an another clinical trial
* Blood selenium level less than 85 mcg/L
* Pregnant or intends to become pregnant
D: Inclusion Criteria:

* 9.0 to 9.9 mo of age

Exclusion Criteria:

* severe anemia
* severely malnourished
* presence of bipedal oedema
* severe illness
* congenital abnormalities
* chronic medical condition
* known HIV infection of mother or infant
* history of peanut allergy
* history of anaphylaxis or serious allergic reaction to any substance

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Zinc Therapy in Zinc Deficient HIV Positive Drug Users
Brief Summary: Zinc deficiency is prevalent in HIV infected individuals who abuse drugs. The purpose of this study is to determine if zinc therapy will prevent immune failure in HIV infected individuals who abuse drugs and have low plasma zinc levels.


Options:
A: Inclusion Criteria:

1. HIV seropositive diagnosed with standard techniques
2. Age for perinatally-acquired HIV/AIDS Group (PA subjects): 5.0 to 24.9 y
3. Age for non-perinatally-acquired HIV/AIDS Group (non-PA subjects): 15.0 to 24.9 y
4. In usual state of good health (no hospitalizations, emergency room or unscheduled acute illness visits for 2 weeks prior)
5. Subject and/or family commitment to the 3-month study

Exclusion Criteria:

1. Other chronic health conditions that may affect growth, dietary intake, and/or nutritional status
2. Pregnancy
3. Participation in another HIV intervention study with impact on 25D serum concentrations
4. Use of vit D supplementation (subjects willing to discontinue supplementation will become eligible after a 2-month washout period)
5. Baseline elevated serum calcium concentration
6. Non-English speaking
B: Inclusion Criteria:

* men or women aged \>=18 years old
* HIV-positive
* initiating anti-retroviral therapy at the time of randomization or have been on highly active anti-retroviral therapy (HAART) for no more than 6 months
* have no intention of migrating, or re-locating \>= 20 km outside of the Infectious Disease Institute (IDI), or Kiswa Health Center within the next 18 months after enrollment
* agree to allow home visit(s) and subsequent follow-up contacts as part of the study
* provide written informed consent

Exclusion Criteria:

* pregnant Women
* individuals from whom we are unable to obtain written informed consent will be excluded from the study. For example, patients that are extremely ill and unable to consent will be excluded.
C: Inclusion Criteria:

* HIV infected
* Drug User
* Blood zinc level greater than 0.35 mcg/mL and less than 0.75mcg/ml

Exclusion Criteria:

* Currently participating in an another clinical trial
* Blood selenium level less than 85 mcg/L
* Pregnant or intends to become pregnant
D: Inclusion Criteria:

* HIV infected
* HIV-RNA \< 400 copies/ml at study entry and for 12 wks. prior
* 25-hydroxyvitamin D level \<20
* On a stable anti-retroviral (ARV) regimen for at least 12 weeks prior to study entry

Exclusion Criteria:

* Pregnancy or Breast Feeding
* Diabetes
* Creatinine Clearance \<50
* Any active infectious or inflammatory condition
* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 within 6 months prior to study entry

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Soft Drink, Milk and Obesity in Chilean Children
Brief Summary: The primary aim of this randomized controlled trial is to evaluate the effects of replacing habitual consumption of sugar-sweetened soft drinks with milk over 16 weeks.


Options:
A: Inclusion Criteria:

* Male or female, age 8 to 10 years
* Tanner Stage I
* BMI between 85th and 95th percentiles for age and gender
* Consuming at least 2 servings/day of sugar-sweetened beverages
* Willingness to consume milk instead of sugar-sweetened beverages for 16 weeks
* Able to read Spanish and accurately complete dietary assessments

Exclusion Criteria:

* Presence of a serious underlying medical condition
* Taking any medication that affects body weight
* History of lactose intolerance or milk protein allergies
* History of an eating disorder
B: Inclusion Criteria:

* Afterschool programs in Boston MA serving at least 40 children ages 5-12 years operating the full school year between September and June
* Afterschool programs serving a snack to children
* Children between the ages of 5 and 12 years
C: Inclusion Criteria:

* purchase \>75% of groceries at targeted supermarket (regular customer)
* at least one child \<= 18 years old living at home

Exclusion Criteria:

* not fluent in Spanish or English
* no address or phone for contact
D: Inclusion Criteria:

* one obese or two overweight parents, 1 year old child

Exclusion Criteria:

* weight effecting diseases

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Treatment of Adolescents With Anorexia Nervosa
Brief Summary: This study will compare the effectiveness of family-based therapy versus individual psychotherapy for the treatment of adolescent anorexia nervosa.


Options:
A: Inclusion Criteria:

* Meets DSM-IV criteria for anorexia nervosa
* Lives with at least one parent who is willing to participate
* Medically stable
* Adequate transportation to clinic
* Proficient at speaking, reading, and writing English

Exclusion Criteria:

* Currently undergoing treatment or taking medication that may affect eating or weight
B: Inclusion Criteria:Diagnosis of anorexia nervosa with Ideal Body Weight \>75% Exclusion Criteria:Current psychotic illness or mental retardation that would prohibit the use of psychotherapy Medically unstable for outpatient treatment
C: Inclusion Criteria:

* Meets DSM-IV-TR criteria for anorexia nervosa (restricting or binge-purge subtype), with or without amenorrhea after inpatient admission
* Has achieved 90% of ideal body weight or BMI greater than or equal to 19.5 kg/m2 for at least 1 week after inpatient admission
* Medically stable

Exclusion Criteria:

* Chronic psychotic or bipolar I disorder requiring ongoing treatment with antipsychotic or mood stabilizer
* Diagnosis of obsessive compulsive disorder in which the symptoms are clearly unrelated to eating disorders
* Current substance abuse
* Current use of psychotropic medication
* Acute suicidality (suicidality or self-injury in the 3 months before study entry)
* Serious medical illness
D: Inclusion Criteria:

* Anorexia nervosa
* Subthreshold anorexia nervosa
* Bulimia nervosa
* Subthreshold Bulimia nervosa
* Nonpregnant
* No prescribed psychotropic medication
* No concurrent psychiatric treatment
* No indications for inpatient treatment including suicide risk, significant metabolic or cardiac complications
* Willingness to refrain from seeking other forms of ED treatment until completing the intervention and post-treatment data collection protocols
* Negative lifetime history for schizophrenia, other DSM-IV Axis I psychotic disorders and mental retardation

Exclusion Criteria:

* Acute and chronic medical conditions other than those related to the ED
* Any other concurrent DSM-IV Axis I disorder at threshold level

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Oral Sucrose Analgesia During Routine Immunizations at 6 Weeks and 4 Months of Age
Brief Summary: The study explores the potential benefits of a sugar water solution for decreasing pain in infants during routine immunizations.


Options:
A: Inclusion Criteria:

* healthy newborn infants ≥36 weeks gestation
* infants born to mothers with diabetes (type 1, type 2, or gestational diabetes that is diet-controlled or insulin-dependent)and infants born to mothers without diabetes

Exclusion Criteria:

* Admission to the neonatal intensive care unit
* plan to undergo circumcision during the study period
* major congenital or neurological anomalies
* clinical diagnosis of birth asphyxia or seizures
* receiving analgesics or sedatives
B: Inclusion Criteria:

* Written informed consent.
* Gestational age of 37 0/7 to 41 6/7 weeks.
* Patients cared in rooming-in, with post-natal age of 12 to 72 hours of life.
* Adequate for gestational age and healthy infants.
* No other painful stimuli before study except for Vitamine K injection soon after birth.
* Interval from last feeding between 30 and 60 minutes.

Exclusion Criteria:

* Mothers that used opioid at gestation labor or birth.
* Delivery under general anesthesia.
* Apgar score less than seven in the 1st or 5th minute of life.
* Neonates that received any venous, arterial, capillary or spinal puncture.
* Any congenital malformation or CNS abnormality.
C: Inclusion Criteria:

* Term neonates, gestational age 37-42 weeks
* Apgar \>= 7
* Not fed in the last 30 minutes
* Informant consent

Exclusion Criteria:

* Congenital malformation
* Born in Caesarian Section in General Anaesthesia
* Maternal use of opioids
* Administration of Naloxone, Phenobarbital in the previous 48 hours
* Impossibility of breastfeeding
D: Inclusion Criteria:

* Currently between 2 and 4 months of age
* Birth between 37 and 42 weeks' completed gestation;
* Birth weight greater than 2.5 kg
* No evidence of acute or chronic disease processes.

Exclusion Criteria:

* They are experiencing concurrent illness
* They received an analgesic/sedative 6 hours prior to the office visit
* The infant has breast fed 30 minutes prior to the visit or wishes to breast feed during or immediately after the immunization
* The infant has been introduced to solid food
* The infant may not receive a pacifier
* The infant is diagnosed with a major congenital disorder where the behavioral responses to painful stimuli may be altered
* Language barriers preclude the process of obtaining parental consent.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Inclusion Criteria:

* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

* Subjects with clinically significant, recent cardiovascular disease.
B: Inclusion Criteria:

* Smokers

Exclusion Criteria:

* Coronary artery disease
* Heart failure
* Diabetes mellitus
* Dyslipidemia
C: Inclusion Criteria:

* Subjects must have smoked an average of at least ten cigarettes per day during the past year
* No period of abstinence greater than three months in the past year

Exclusion Criteria:

* Subjects with history of clinically significant cardiovascular disease
* Subjects with uncontrolled hypertension.
D: Inclusion Criteria:

* Participants must have stable, documented cardiovascular disease (including at least one of the following diagnosed \> 2 months prior to the Screening visit - angina, myocardial infarction (MI), revascularization, transient ischemic attack (TIA), and peripheral vascular disease (PVD).
* Participants that smoke \> 10 cigarettes / day.

Exclusion Criteria:

* Participants with unstable cardiovascular disease
* Cardiovascular events in the past 2 months
* Moderate or severe chronic obstructive pulmonary disease (COPD)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Inclusion Criteria:

* Subjects must have smoked an average of at least ten cigarettes per day during the past year
* No period of abstinence greater than three months in the past year

Exclusion Criteria:

* Subjects with history of clinically significant cardiovascular disease
* Subjects with uncontrolled hypertension.
B: Inclusion Criteria:

* At least 18 years old
* Able to get to research lab in Burlington, Vermont or Omaha, Nebraska
* Daily smoker
* Smoke at least 8 cigarettes per day
* No reduction in smoking in last 30 days
* No intention to quit in the next 30 days
* Never used Varenicline before
* Not currently using smoking cessation medications or nicotine replacement therapy
* Willing to use Varenicline for at least 2 weeks
* Fluent in English

Exclusion Criteria:

* Cannot be currently pregnant or breastfeeding
* Kidney disease
* Frequent nausea
* On certain medications for asthma and/or depression
* Another household member in study
C: Inclusion Criteria:

* Age ≥18 years Smoking ≥ 10 cigarettes per day Patients with disease conditions known to be related to smoking: e.g.coronary heart diseases, COPD, lower extremity arterial disease, etc

Exclusion Criteria:

* Smokers whose follow-up during the duration of the study, in a predictable way, cannot be assured.
* smokers having been treated by bupropion ( Zyban) during two months preceding the inclusion
* persons under TSN, neuroleptic, substitute treatments in OPINOIDES, under anticoagulants-non-equilibrating,
* encircled woman
* breast-feeding woman
* Contraindication usual of the TSN
D: Inclusion Criteria:

* Must be at least 18 years of age
* Be in good general health
* Must meet Diagnostic and Statistical Manual-IV (DSM-IV) diagnostic criteria for nicotine dependence
* Be currently smoking \> 15 cigarettes/day, and have smoked cigarettes for the past 5 years
* Subjects must be motivated to quite smoking
* If female and of child bearing potential, agrees to use birth control and subject
* Subject must be able to understand and provide written informed consent.

Exclusion

Criteria:

* Please contact site for more information

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Seven-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Three Doses of CP-526,555 ( 0.3 mg QD, 1 mg QD, and 1 mg BID ) in Comparison With Zyban in Smoking Cessation
Brief Summary: The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.


Options:
A: Inclusion Criteria:

* Diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
* Enrolled in services at the research site for a minimum of 3 months
* Regular smoker (approximately 10 cigarettes for the past 5 years) with a history of at least 1 quit attempt
* Fluent in English

Exclusion Criteria:

* Regular use of e-cigarettes in the past month
* Current interest/plan to quit smoking
* Regular use of nicotine replacement therapy to quit smoking or use of bupropion or varenicline to quit smoking
* Use of emergency room or hospitalization for psychiatric reasons in the past 30 days
B: Inclusion Criteria:

* patients who are assessed in pre-admission clinic and scheduled for elective surgical procedures within the next 8 to 30 days
* patients should be over 18 yrs of age
* patients should have smoked an average 10 cigarettes/day or more during the previous year and had no period of smoking abstinence longer than 3 months in the past year

Exclusion Criteria:

* current pregnancy (or willingness to be pregnant within the next year after the start of the medication)
* current breastfeeding
* major depression, panic disorder, psychosis, or bipolar disorder within the prior year
* use of nicotine replacement or bupropion within the previous 3 months cardiovascular disease within the past 6 months
* a serious or unstable disease within the past 6 months
* drug or alcohol abuse or dependence within the past year
* use of tobacco products other than cigarettes or marijuana use within the previous month
* participating in any other studies
* patients who cannot understand English or have any form of cognitive impairment
C: Inclusion Criteria:

* healthy smokers
* unwilling to quit
* age 18-60 years
* smoking ≥ 15 cig/day for at least 5 years
* exhaled CO level of ≥ 15 ppm
* FTND ≥ 5

Exclusion Criteria:

* alcohol and illicit drug use
* breastfeeding or pregnancy
* major depression or other psychiatric conditions
* previous experience with ENDD
* recent myocardial infarction
* angina pectoris
* high blood pressure (BP\>140mm Hg systolic and/or 90mmHg diastolic)
* diabetes mellitus
* severe allergies
* poorly controlled asthma or other airways diseases
D: Inclusion Criteria:

* Subjects must have smoked on average of at least ten cigarettes per day during the past year
* Subjects must have no period of abstinence greater than three months in the past year

Exclusion Criteria:

* Subjects with any history of cardiovascular disease
* Myocardial infarction
* Significant arrhythmias
* Poorly controlled hypertension

Answer: D